Arypsa Stock

Arypsa ROE

The Return on Equity (ROE) of Arypsa (APYI) as of Aug 7, 2026 is -76.41 %.

ROE

-76.41 %

Last updated:

In 2026, Arypsa's return on equity (ROE) was -76.41 %, a % increase from the - ROE in the previous year.

Access this data via the Eulerpool API

Arypsa Stock analysis

What does Arypsa do? Aspyra Inc. is an American company based in California that specializes in the development and distribution of medical IT solutions. The history of Aspyra dates back to 1993 when the company was founded as an independent provider of medical imaging technology. In the following years, Aspyra expanded its business model and focused on developing integrated solutions for the healthcare industry. Today, the company offers a wide range of products and services such as RIS, PACS, LIS, and teleradiology systems that are used by hospitals, clinics, and medical practices worldwide. Aspyra also has specialized divisions within the company that focus on specific solutions. One of these divisions is INSIGHT, which specializes in the development of LIS systems. These solutions provide a specialized software platform that simplifies laboratory management and the workflow of medical tests and results. Another important division of Aspyra is the teleradiology department, which transmits specialized medical imaging findings and reports via telecommunication systems from one radiologist to another. This is particularly advantageous in providing care to patients in rural areas or areas with limited healthcare services. Aspyra also offers various software products, including the PACS system, the Radiology Information System (RIS), and the LIS system. The PACS system allows for the capture of medical images and provides them in electronic form, while the RIS system facilitates the management process of radiology departments and administrative processes related to the data. The LIS system, specifically tailored to the needs of laboratories, also supports the creation of contingency reports and better quality assurance. In recent years, Aspyra has also formed partnerships with other companies in the healthcare industry to expand its product portfolio. This includes a recent collaboration with Healthline Networks and First Databank to combine its IT systems with health data and information from third-party specialists. Aspyra has established itself as a leading provider of medical IT solutions and offers its customers a wide range of products and services. Thanks to its expertise in the healthcare industry, the company has been able to expand its presence in the global market and establish itself as an important partner for medical facilities in North America and Europe. Arypsa is one of the most popular companies on Eulerpool.

ROE Details

Decoding Arypsa's Return on Equity (ROE)

Arypsa's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Arypsa's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Arypsa's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Arypsa’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Arypsa stock

Return on Equity (ROE) of Arypsa is -76.41 % in 2026.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Arypsa since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Arypsa with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Arypsa

All Key Metrics — Arypsa